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Abstract
Background: Accumulating evidence suggests that inflammation plays an important role in the
progression of Parkinson's disease (PD). Among many inflammatory factors found in the PD brain,
cyclooxygenase (COX), specifically the inducible isoform, COX-2, is believed to be a critical
enzyme in the inflammatory response. Induction of COX-2 is also found in an experimental model
of PD produced by administration of 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Method: COX-2-deficient mice or C57BL/6 mice were treated with MPTP to investigate the
effects of COX-2 deficiency or by using various doses of valdecoxib, a specific COX-2 inhibitor,
which induces inhibition of COX-2 on dopaminergic neuronal toxicity and locomotor activity
impairment. Immunohistochemistry, stereological cell counts, immunoblotting, an automated
spontaneous locomotor activity recorder and rotarod behavioral testing apparatus were used to
assess microglial activation, cell loss, and behavioral impariments.
Results: MPTP reduced tyrosine hydroxylase (TH)-positive cell counts in the substantia nigra pars
compacta (SNpc); total distance traveled, vertical activity, and coordination on a rotarod; and
increased microglia activation. Valdecoxib alleviated the microglial activation, the loss of TH-
positive cells and the decrease in open field and vertical activity. COX-2 deficiency attenuated
MPTP-induced microglial activation, degeneration of TH-positive cells, and loss of coordination.
Conclusion: These results indicate that reducing COX-2 activity can mitigate the secondary and
progressive loss of dopaminergic neurons as well as the motor deficits induced by MPTP, possibly
by suppression of microglial activation in the SNpc.
Introduction
Parkinson's disease (PD) is a chronic and progressive
motor disorder marked by degeneration of dopaminergic
neurons in the substantia nigra pars compacta (SNpc).
Increased inflammation and oxidative stress have been
implicated in this neuronal death as elevated levels of
cyclooxygenase-2 [1] and reactive microglia [2] have been
found in PD brains. Cyclooxygenase, present as COX-1
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and COX-2 isoforms, is the rate-limiting enzyme in ara-
chidonic acid-derived prostaglandin production [3,4].
While COX-1 is constitutively expressed in most tissues,
COX-2 is induced during pathophysiological responses to
inflammatory stimuli such as bacterial endotoxin, inter-
leukin-1 (IL-1), and various growth factors [5,6].
During the process of prostaglandin production, reactive
oxygen species are generated as by-products [7] which, in
addition to endotoxin, mitogens, cytokines, and certain
inflammatory mediators, can activate microglia [8].
Microglia are also activated by oxidative stress [9]. Micro-
glial activation causes the release of free radicals [10] and
of inflammatory cytokines, including IL-1β, IL-6, and
tumor necrosis factor-α [11]. Under normal circum-
stances, a response by microglia is protective in fighting
off pathogens; however, under pathological conditions
induced by certain insults – including oxidative stress,
excitotoxicity from ion imbalance, and trauma – micro-
glia can be over-stimulated and produce excessive cyto-
toxic agents that damage neurons, stimulating
overexpression of neuronal and/or microglial COX-2
[1,10-17]. Co-propagation of COX-2 expression and
microglial activation may cause secondary damage to neu-
rons and the surrounding cellular environment; therefore,
pharmacological intervention to stop the positive feed-
back loop between COX-2 and microglial activation may
prevent secondary injury induced by an excessive inflam-
matory response and oxidative stress.
In several epidemiological studies, nonsteroidal anti-
inflammatory drugs have shown protective effects in
reducing the risk of neurodegenerative disease such as
Alzheimer's disease [8,18] and PD [19]. In the present
study, we tested the hypothesis that excessive COX-2
aggravates MPTP-induced toxicity by perpetuation of the
inflammatory response, which leads to secondary neuro-
nal cell death in the SNpc. This study was designed to
explore the role of COX-2-related inflammation in the
pathogenesis of PD and to test the possibility of COX-2
inhibitors as a potential therapeutic drug for PD. Using an
MPTP mouse model, C57BL/6N mice treated with thera-
peutic doses of valdecoxib showed improved cellular sur-
vival and behavioral function compared to vehicle
controls. Similar results were obtained using COX-2-defi-
cient mice. Both inhibition of COX-2 and genetic defi-
ciency of COX-2 reduced SNpc microglial activation and
mitigated MPTP-induced neurotoxicity on dopaminergic
neurons in the SNpc.
Materials and methods
Animals and treatments
The development of COX-2 knockout mice has been pre-
viously described [20]. COX-2-deficient C57BL/6 mice
were established at the National Institute of Environmen-
tal Health Science, Research Triangle Park, NC, USA, from
which breeders were obtained to produce new breeding
colonies at the University of Kentucky. Mice were kept on
a 12:12 hour light:dark cycle and fed ad libitum. All COX-
2 knockout (KO) -/-, heterozygous (HT) +/-, and wild type
(WT) +/+ controls used were male littermates from a
number of simultaneous matings and were seven to nine
months old, weighing 25–35 grams. The genotype was
determined by PCR. In addition to these sets of mice,
male retired C57BL/6N breeders (aged seven to nine
months, weighing 25–35 grams, Charles River Breeding
Laboratories) were also used.
For each study, 8–12 mice per group received MPTP·HCL
(Sigma-Aldrich, St. Louis, MO) at a dosage of 4 × 15 mg/
kg i.p. at 1.5 hr intervals and were killed one or two weeks
after the last injection. The non-MPTP treated controls
received a comparable volume of 0.9% saline. MPTP han-
dling and safety measures were in accordance with our
Division of Laboratory Animal Resources Standard Oper-
ating Procedure and the Institutes of Health procedure for
working with MPTP or MPTP-treated animals. Adminis-
tration of valdecoxib (Bextra, Pharmacia, Chicago, IL) was
modified from a published method [21]: 10, 30 or 50 mg/
kg of valdecoxib was mixed with and administered as a
cheese pellet, daily at 24-hour intervals from two weeks
before MPTP injection until the end of the experiment. All
procedures involving animals are approved by the Institu-
tional Animal Care and Use Committee at the University
of Kentucky and are in strict accordance with the National
Institutes of Health Guidelines for the Care and Use of Labo-
ratory Animals.
Genotyping of COX-2-deficient mice
We performed genotyping with a standard protocol to
identify wild-type, heterozygous, and homozygous COX-
2-deficient mice. Four weeks after birth, segments of
about three to five millimeters of mouse tails were
digested with lysis buffer and proteinase-K at 55°C over-
night (Genomic DNA purification kit, Gentra systems,
Minneapolis, MN). After RNase treatment, DNA was sep-
arated by phenol-chloroform extraction and ethanol pre-
cipitation. PCR was performed with the following COX-2
specific primers (invitrogen, Carlsbad, CA):
COX-2 WT Forward: 5'-ACA CAC TCT ATC ACT GGC
ACC-3'
COX-2 KO Forward: 5'-ACG CGT CAC CTT AAT ATG CG-
3'
COX-2 Reverse: 5'-TCC CTT CAC TAA ATG CCC TC-3'
The thermal cycler (Eppendorf Mastercycler gradient,
eppendorf, Hamburg, Germany) was programmed as fol-
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lows: one cycle at 95°C for five minutes, and 30 cycles of
94°C for 30 seconds, 60°C for one minute, and 72°C for
90 seconds, followed by a final extension cycle of 72°C
for seven minutes. PCR is expected to yield fragments of
760 and 900 bp for the COX-2 wild-type and knockout
alleles, respectively.
Immunohistochemistry
Brains were sectioned at 30 µm thickness on a sliding
microtome for free-floating tissue sections. Every sixth sec-
tion from a given area was stained with polyclonal anti-
bodies (Ab) against neuronal TH (1:2000 Pelfreez, Roger,
AR) or Mac-1 (1:1000 Serotec, Oxford, UK). Sections were
incubated in 4% normal serum in PBS for 30 minutes.
After this blocking step, the sections were incubated over-
night in PBS containing 0.025% Triton X-100, 1% normal
serum, and the primary antibodies at 4°Celcius. The avi-
din-biotin immunoperoxidase method with 3,3'-diami-
nobenzidine tetrahydrochloride as the chromagen was
used to visualize immunoreactive cells (ABC Kits, Vector
Laboratory, Burlingame, CA). For Nissl-staining, SNpc
sections were stained with cresyl violet. Sections were then
mounted on gelatinized slides, left to dry overnight, dehy-
drated in ascending alcohol concentrations, and mounted
on Permount (Fisher Scientific, Fair Lawn, NJ).
Western blot analysis
Cellular proteins were extracted from the striatal samples
with an extract buffer containing 0.5% Triton X-100 and
protease-inhibitor cocktail (1:1000, Sigma-Alsrich, St.
Louis, MO). The tissues were homogenized in this buffer
with the Fisher model 100 sonic dismembranator and put
on ice for one hour. The soluble extracts were separated by
centrifugation at 11,500 rpm for five minutes at 4°Cel-
cius. Equal amounts of protein samples (20 µg) were
mixed with the loading buffer (60 mM Tris-HCl, 2% SDS,
and 2% β-mercaptoethanol, pH 7.2), boiled for 4 min-
utes, resolved by SDS-polyacrylamide gels, and trans-
ferred to a nitrocellulose filter (Millipore, Bedford, MA)
using a semidry blotting apparatus (Bio-Rad Laboratories,
Hercules, CA). After blocking with a solution containing
5% nonfat milk, the filters were incubated with TH
(1:1000 Boehringer-Mannheim, Indianapolis, IN) or β-
actin (Sigma, St. Louis, MO) antibodies for detection of
the level of dopaminergic neuronal terminals, and for
normalization of the loading protein. The signal was vis-
ualized by enhanced chemiluminescence according to the
instructions of the manufacturer (Amersham Biosciences,
Little Chalfont Buckinghamshire, England) by employing
a goat anti-rabbit or goat anti-mouse secondary antibody
conjugated with hydrogen peroxidase (Sigma-Aldrich, St.
Louis, MO). Signal specificity was insured by omitting
each primary antibody in a separate blot, and loading
errors were corrected by measuring β-actin immunoreac-
tive bands in the same membrane. The density measure-
ment of each band was performed with Scion image
software (Scion Corporation, Frederick, MD). Background
samples from an equivalent area near each lane were sub-
tracted from each band to calculate mean band density.
Cell counting
The total number of TH- and Nissl-stained SNpc neurons
and Mac-1-stained SNpc activated microglia were counted
in sections from six to eight mice per group using the opti-
cal fractionator method for unbiased cell counting. The
optical fractionator method of cell counting combines the
optical dissector with fractional sampling, and is unaf-
fected by the volume of reference (i.e., SNpc) or the size of
the counted elements (i.e. neurons) [22]. Cell counts were
performed by using a computer-assisted image analysis
system consisting of a Zeiss Axioskop2Plus photomicro-
scope equipped with a MS-2000 (Applied Scientific
Instrumentation, Eugene, OR) computer-controlled
motorized stage, a Sony DXC-390 (Japan) video camera,
a DELL GX260 workstation, and the Optical Fractionator
Project module of the BIOQUANT Stereology Toolkit
Plug-in for BIOQUANT Nova Prime software (BIO-
QUANT Image Analysis Corporation, Nashville, TN). Cell
counting was done on both sides of SNpc of every sixth
section throughout the entire extent of the SNpc. Each
midbrain section was viewed at low power (× 10 objec-
tive), and the SNpc was outlined by using a set of anatom-
ical landmarks. The cell numbers were counted at high
power (× 40 objective). Adjacent sections immediately
caudal and rostral to the sections used for TH staining
were stained and counted for Nissl-stained neurons and
Mac-1-stained activated microglia. TH- and Nissl-stained
neurons were counted only when their nuclei were opti-
mally visualized within one focal plane. Nissl-stained
neurons were differentiated from non-neuronal cells by
the clearly defined nucleus, cytoplasm, and a prominent
nucleolus. After all of the cells were counted, the total
numbers of neurons or activated microglia in the SNpc
were automatically calculated by the module using the
formula described by West et al. [22].
Behavioral analysis and evaluation of locomotor activity
Apparatus
During the light period, locomotor activity was assessed
using four automated activity chambers (Model RXYZCM-
8, Accuscan Instruments, Columbus, OH). Each chamber
consisted of a 41 × 41 × 31-cm3 Plexiglas box with a grid
of infrared beams mounted horizontally every 2.5 cm and
vertically every 4.5 centimeters. The monitors were con-
nected to a Digiscan Analyzer (Model DCM-8, Accuscan
Instruments) that transmitted the number of beam breaks
(activity data) to a computer. During operation, the pat-
tern of beam interruptions was recorded for six consecu-
tive 5-minute periods and analyzed by the computer.
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TH-positive neurons are more resistant to MPTP in mice treated with a selective COX-2 inhibitor (valdecoxib)Figure 1
TH-positive neurons are more resistant to MPTP in mice treated with a selective COX-2 inhibitor (val-
decoxib). A: Photomicrographs of representative SNpc sections stained with an antibody against TH. The SNpc tissues were 
collected 14 days post-MPTP injection. The MPTP (4 × 15 mg/kg, 1.5 hr interval, i.p.)-treated mice have fewer TH-positive neu-
rons compared to the saline groups. However, valdecoxib treatment reduced the neuronal loss, especially at a higher dose (30 
or 50 mg/kg daily). B: MPTP administration led to significant loss of TH-positive neurons numbers by 78 percent for vehicle 
and by only about 68, 56, and 42 percent for 10, 30 and 50 mg/kg valdecoxib-treated mice, respectively. Among the MPTP-
injected mice, the valdecoxib-treated mice had 10 to 32 percent more TH-positive neurons than the vehicle-treated mice. 
Nissl stain shows similar trends (C&D). E: Inhibition of COX-2 reduced the MPTP-induced loss of the striatal TH immunore-
activity. F: After MPTP treatment, the vehicle-treated mice had significantly reduced TH immunoreactivity compared to the 
saline-treated mice (***p < 0.001). Among the MPTP-injected mice, the valdecoxib (30 mg/kg daily)-treated mice had at least 
30% higher TH immunoreactivity than the vehicle-treated mice. Data are means ± SEM for six to eight mice per group, **p < 
0.01 and ***p < 0.001 compared to saline+vehicle group; #p < 0.05, ##p < 0.01 and ###p < 0.001 compared to MPTP+vehicle 
group, by ANOVA with subsequent Bonferroni for multiple comparisons. Scale bar, 100 µm.
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Ablation of COX-2 protects TH+ Neurons in SNpc from MPTPFigure 2
Ablation of COX-2 protects TH+ Neurons in SNpc from MPTP. A: In COX-2-/- (KO) mice, dopaminergic neurons 
are protected from MPTP neurotoxicity. Representative TH immunocytochemistry shows a marked loss of TH-positive neu-
rons in SNpc of COX-2 +/+ (WT) mice compared to both COX-2 -/- (KO) and COX-2 +/- (HT) mice after MPTP treatment. 
B: MPTP treatment leads to a significant loss in number of TH+ neurons. TH-positive cells in the SNpc were bilaterally 
counted under 40 × objective. Nissl stain shows similar trends (C&D). E: COX-2 deficiency reduced the MPTP-induced loss 
of striatal TH immunoreactivity. F: MPTP-treated WT mice had significantly reduced TH immunoreactivity compared to the 
saline WT (*p < 0.05). Among the MPTP-treated mice, the COX-2-deficient mice had at least 30% higher TH immunoreactivity 
than the WT mice. Data are means ± SEM for six to eight mice per group, *p < 0.05, **p < 0.01 and ***p < 0.001 compared to 
saline+vehicle group; #p < 0.05 and ##p < 0.01 compared to MPTP+vehicle group, by ANOVA with subsequent Bonferroni for 
multiple comparisons. Scale bar, 100 µm.
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Behavioral measures
Prior to valdecoxib administration, animals were allowed
to habituate to the locomotor activity chambers during
daily 30-min sessions over six consecutive days. Two
measures of overall locomotor activity were obtained dur-
ing the behavioral sessions: total distance traveled and
MPTP-induced microglial activation is inhibited by the selec-tive COX-2 inhibitor valde oxibFigure 3
MPTP-induced microglial activation is inhibited by 
the selective COX-2 inhibitor valdecoxib. A: At 14 
days post-MPTP injection, there was a high level of microglial 
activation in the SNpc. Unlike the vehicle group, mice treated 
with valdecoxib have diminished microglial activation. Pic-
tures on the right are magnified photographs of the pictures 
on the left side. In contrast to inactivated striped microglia in 
MPTP+valdecoxib and control saline sections, activated 
microglia in MPTP+vehicle sections have a rounder body, fat-
ter processes and denser stain. B: MPTP treatment leads to a 
significant increase in the number of activated microglia in 
mice receiving vehicle or the lowest dose of valdecoxib (10 
mg/kg daily) but not the higher dose of valdecoxib (30 or 50 
mg/kg daily). Activated microglia in the SNpc were bilaterally 
counted under a 40 × objective. Data are means ± SEM for 
six to eight mice per group, ***p < 0.001 compared to 
saline+vehicle group; ###p < 0.001 compared to 
MPTP+vehicle group, by ANOVA with subsequent Bonfer-
roni for multiple comparisons. Scale bar, 100 µm.
Ablation of COX-2 reduces MPTP-induced microglial activa-tion 7 days post-MPTP inj ctionFigure 4
Ablation of COX-2 reduces MPTP-induced microglial 
activation 7 days post-MPTP injection. A: Seven days 
after MPTP treatment, COX-2 +/+ mice had a local increase 
of microglial activation in the SNpc, which is shown with 
immunohistochemical stains for Mac-1, compared to saline-
treated or MPTP-treated COX-2 +/- and -/- mice. The mag-
nified right panels show activated microglia. In contrast to 
inactivated striped microglia in MPTP-treated COX-2-defi-
cient and control saline sections, activated microglia in 
MPTP-treated COX-2 wild-type have a rounder body, fatter 
processes and denser stain. B: MPTP treatment leads to a 
significant increase in the number of activated microglia in 
the WT relative to the HT and KO mice. Activated microglia 
in the SNpc were bilaterally counted under a 40 × objective. 
Data are means ± SEM for six to eight mice per group, ***p < 
0.001 compared to saline+vehicle group; ###p < 0.001 com-
pared to MPTP+vehicle group, by ANOVA with subsequent 
Bonferroni for multiple comparisons. Scale bar, 100 µm.
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TH-positive neuronal counts have strong negative correlation with the number of Mac-1-stained activated microglia and COX-2Figure 5
TH-positive neuronal counts have strong negative correlation with the number of Mac-1-stained activated 
microglia and COX-2. Figures 5A-D show results from the study from valdecoxib-treated mice and Figures 5E-H show 
results from the study from COX-2-deficient mice. The results from the correlation matrix shown in panels A and E are tabu-
lated in panels B and F, respectively. As expected, the number of viable TH-positive neurons was strongly correlated with the 
number of neurons counted with the Nissl stain (r > 0.90). Importantly, the number of activated microglia was strongly nega-
tively correlated with TH- and Nissl-stained neurons, both r ≈ -0.80 (p < 0.05, Pearson correlation test, n = 6–8 per group). 
The result from the correlation matrix shown in C is indicated in D. Similar analysis as in A and B was used, but included only 
MPTP-treated values and assigned value of 0 for no treatment and 10, 30 and 50 for increasing dosage of valdecoxib. The 
results were similar to those of A and B with a positive correlation of the amount of daily valdecoxib to TH- and Nissl-stained 
neuronal numbers (both rs ≥ 0.80) and a strong negative correlation of the dosage of valdecoxib to microglial activation (rs = -
0.841, p < 0.05 Spearman correlation statistic, n = 6–8 per group). The result from the correlation matrix shown in G is indi-
cated in H. A similar analysis as in E and F was used, but included only MPTP-treated values and assigned values of 1.0, 0.5 and 
0.0 to COX-2 WT, HT and KO, respectively. The results were similar to those of E and F with strong negative correlation of 
COX-2 to TH- and Nissl-stained neuronal numbers (both rs ≈ -0.90) and strong positive correlation of COX-2 to microglial 
activation (rs = 0.886, p < 0.05 Spearman correlation statistic, n = 6–8 per group).
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vertical activity. Total distance traveled is quantified as the
sum of the distance measured (in centimeters) across the
30-min recording period. Vertical activity is quantified as
the sum of the number of vertical photobeam interrup-
tions across the six 5-minute intervals.
Rotarod testing
The Rotarod treadmill (MED Associates Inc, St. Albans,
VT.), designed to measure motor performance and coordi-
nation, consists of a 3.6-cm diameter cylindrical treadmill
connected to a computer-controlled stepper motor-driven
drum that can be programmed to operate at a constant
speed or in a defined acceleration mode. When the animal
falls off the rotating drum, individual sensors at the bot-
tom of each separate compartment automatically record
the amount of time (in seconds) spent on the treadmill.
Mice were trained two consecutive days before MPTP
injections in acceleration mode (2–20 rpm) over five min-
utes. The training was repeated with a fixed speed (16
rpm) until the mice were able to stay on the rod for at least
150 seconds. On day 2, 4, and 6 after MPTP injections,
mice were assessed for their coordination capability with
a maximum recording time of 150 seconds. Rotational
speeds of 16, 20, 24, 28, and 32 rpm were recorded in suc-
cession, and the overall rod performance (ORP) for each
mouse was calculated by the trapezoidal method as the
area under the curve in the plot of time on the rod versus
rotation speed [23].
Statistical analysis
All data were analyzed using an IBM-based personal com-
puter statistical package (SYSTAT 10, SPSS Inc, Chicago,
IL). Except for the correlation analyses, all values are
expressed as the mean ± SEM, and differences among
means were analyzed by using one- or two-way analysis of
variance (ANOVA) with time, treatment, or genotype as
the independent factor. When ANOVA showed significant
differences, pairwise comparisons between means were
tested by Bonferroni post hoc testing. Statistical signifi-
cance was set at p < 0.05 for all analyses.
Results
Valdecoxib treatment attenuates MPTP-induced 
dopaminergic neurodegeneration
To determine the neuroprotective effect of COX-2 inhibi-
tors against MPTP-induced neurotoxicity, TH-positive and
Nissl-stained neurons in the SNpc were stereologically
quantified. Treatment with valdecoxib did not affect the
number of TH-positive and Nissl-stained neurons in the
SNpc (Fig. 1A &1C), and a stereological analysis showed
no significant difference among the saline-injected groups
(Fig. 1B &1D). Fourteen days after the MPTP injections,
there was a clear MPTP-associated toxic effect on the SNpc
as revealed by diminished TH- and Nissl-stained neurons
in sections from MPTP-treated mice, and the loss was sig-
nificantly reduced by treatment with valdecoxib (Fig. 1A).
Treatment with MPTP induced about 78% TH-positive
cell loss while the various valdecoxib pretreatment groups
showed only about 42–68% loss of TH-positive neurons.
Compared to the saline+vehicle control, there was signif-
icant loss of TH-positive neurons in the MPTP-treated
groups (***p < 0.001) (Fig. 1B). The numbers of TH-pos-
itive neurons remaining in the SNpc after MPTP injection
in the higher doses of valdecoxib-treated mice (30 and 50
mg/kg) are statistically higher than in the MPTP+vehicle
group (#p < 0.05 and ###p < 0.001, Fig. 1B). Nissl stain
showed similar trends and statistical results (Fig. 1C
&1D), suggesting an actual TH-positive neuronal loss
instead of a loss of TH expression. To determine whether
valdecoxib could prevent not only MPTP-induced loss of
SNpc dopaminergic neurons but also the loss of striatal
dopaminergic fibers, we assessed the density of TH immu-
noreactivity in the striata of the different mice (Fig. 1E).
MPTP significantly reduced striatal TH immunoreactivity
compared to the saline control by 70% in the MPTP+vehi-
cle (***p < 0.01) and only about 30% in the MPTP+val-
decoxib mice (Fig. 1F). These findings demonstrate that
valdecoxib protects the nigrostriatal pathway against the
MPTP-induced degeneration of dopaminergic neurons.
COX-2 deficiency attenuates MPTP-induced loss of TH-
positive neurons and neuronal terminals in the 
nigrostriatal system
Because of possible unintended confounding effects asso-
ciated with oral administration of COX-2 inhibitors [24],
we validated the pharmacological approaches using a
genetic approach with COX-2-deficient mice. Immuno-
histochemical studies revealed no differences between
saline-treated mice of different COX-2 genotypes (Fig.
2A). However, among the MPTP-treated mice, the COX-2
knockout (KO) mice exhibited the least TH-positive cell
loss, while the wild-type (WT) mice had the most loss. The
heterozygous (HT) mice showed TH-positive neuronal
survival comparable to the KO mice. MPTP significantly
reduced the number of the TH-positive neurons in the
SNpc, and both the HT and KO mice had significantly
more (20–30%) TH-positive neurons than the WT mice
(#p < 0.05 and ##p < 0.01, respectively). Nissl staining
showed similar trends and statistical results (Fig. 2C
&2D), which indicates a true loss of the TH-positive neu-
rons rather than a decrease in TH expression. To deter-
mine whether deleting the cox-2 genes can prevent MPTP-
induced SNpc dopaminergic neuron loss as well as the
loss of striatal dopaminergic fibers, we assessed the TH
immunoreactivity in striata from the different groups of
mice by Western blot analysis (Fig. 2E). MPTP signifi-
cantly reduced striatal TH immunoreactivity compared
with the control by 80% in the WT (*p < 0.05) but by less
than 50% in the HT and KO mice. Compared to the
MPTP-treated WT mice, both the MPTP-teated HT and KO
Journal of Neuroinflammation 2006, 3:6 http://www.jneuroinflammation.com/content/3/1/6
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mice had statistically higher striatal TH immunoreactivity
(#p < 0.05, Fig. 2F). These results support the effects of
dopaminergic neuronal protection observed with the
selective COX-2 inhibitor valdecoxib and demonstrate
consistency between the pharmacological and genetic
approaches.
The selective COX-2 inhibitor valdecoxib or COX-2 
deficiency abates microglial activation
To investigate potential mechanism of secondary
dopaminergic neuronal death, we performed immunohis-
tochemistry using a microglia-specific antibody (anti-
Mac-1 antibody). A large number of activated microglia,
which had expanded cell bodies and poorly ramified
short and thick processes, were seen in the MPTP+vehicle
group but were not observed in the MPTP+valdecoxib
group or saline-treated groups (Fig. 3). This supports our
hypothesis that inhibition of COX-2 expression during
injury stimuli (MPTP) can reduce microglial activation,
which may lead to secondary degeneration and progres-
sive cell loss. In sections with numerous activated micro-
glia, the SNpc can be distinguished from the surrounding
areas as the activated microglia tend to stay within the
SNpc or along the border of the SNpc. MPTP-induced
microglial activation was clearly observed in the vehicle-
treated mice, but to a lesser extent in the 10, 30 or 50 mg/
kg valdecoxib-treated mice (Fig. 3A). Some activated
microglia could be seen in the saline-treated animals, but
the number of activated microglia was very small com-
pared to the MPTP-treated WT mice (***p < 0.001, Fig.
3B).
To further evaluate the role of COX-2 in modulating
microglial activation in a COX-2 dose-responsive manner,
we performed Mac-1 staining and counted the number of
activated microglia in COX-2-deficient mice receiving
only saline. Saline-treated mice showed no differences
among the COX-2 WT, HT and KO genotypes. MPTP-
induced microglia activation was again observed in the
WT mice but was comparatively less in the HT or KO mice
(Fig. 4A). The numbers of activated microglia in the
MPTP-injected HT and KO mice were significantly (four
and five times) lower than the MPTP-injected WT mice
(###p < 0.001, Fig. 4B). These findings suggest that COX-
2 may play a role in modulating microglial activation.
Dopaminergic neuronal survival is inversely correlated to 
COX-2 and microglial activation
To determine the relationship between the TH-positive
neurons and microglia activation, we performed immu-
nohistochemistry of adjacent SNpc sections of each brain,
counted the cell numbers and studied statistical correla-
tions among them. The sections counted for dopaminer-
gic neurons (Fig. 1A &1B or Fig. 2A &2B) were 30 µm
caudal relative to the sections evaluated for Mac-1 immu-
noreactivity (Fig. 3 or Fig. 4) and 30 µm rostral relative to
the Nissl-stained sections (Fig. 1C &1D or Fig. 2C &2D) of
the same mouse brain. The Pearson correlation matrix
shows the graphic representation of pooled data values
for the number of TH- and Nissl-stained neurons and
Mac-1-stained activated microglia of each mouse from the
valdecoxib study (Fig. 5A) and from the COX-2 deficiency
Selective COX-2 inhibitors alleviate MPTP-induced loss of spontan ous locomotor activity of C57BL/6 miceFigure 6
Selective COX-2 inhibitors alleviate MPTP-induced 
loss of spontaneous locomotor activity of C57BL/6 
mice. On pre-MPTP days (A), there were no statistically sig-
nificant differences among the experimental groups in the 
total distance (cm) mice traveled during each 30-min session. 
By the end of the pre-MPTP treatment period (3 days before 
MPTP injection), mice in all groups traveled similar distances. 
MPTP was administered at day zero. After MPTP treatment 
(B), mice initiated less spontaneous locomotor activity than 
they had prior to MPTP administration. On average, val-
decoxib-treated mice performed up to 25% better than the 
vehicle-treated mice. Data are means ± SEM for eight to 
twelve mice per group pre-MPTP treatment and six to eight 
mice per group post-MPTP treatment. Statistical significance 
was assessed by two-way repeated measures ANOVA with 
Bonferroni post hoc test, **p < 0.01 and ***p < 0.001 com-
pared to the saline+vehicle group; ##p < 0.01 compared to 
MPTP+vehicle group.
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study (Fig. 5E). TH-positive neuron counts were highly
correlated with Nissl-stained neuron counts (r > 0.94),
while microglial activation had strong negative correla-
tions with both TH- and Nissl-cell counts (both with Pear-
son correlation statistic r ≈ -0.80; p < 0.05; Fig. 5B and Fig.
5F). These results suggest a strong co-existence of progres-
sive dopaminergic neuronal degeneration with activation
of microglia.
The relationship of COX-2 inhibition or expression to the
TH-positive neuronal survival and microglia activation
can be inferred from Figures 1 and 3 as well as Figures 2
and 4. Statistically, the correlation of COX-2 to the
number of TH- and Nissl-stained neurons and Mac-1-
stained activated microglia can be determined by the cor-
relation analysis. We ranked the data as 0, 10, 30 or 50 in
accordance with the mg/kg amount of valdecoxib each
mouse received daily. It has been suggested that the level
of COX-2 in the HT mouse is half of the WT [25]; there-
fore, we assigned the WT as having a full expression capa-
MPTP-induced deficit in vertical activity is decreased by selective COX-2 inhibitorsFigure 7
MPTP-induced deficit in vertical activity is decreased 
by selective COX-2 inhibitors. An objective measure of 
the vertical activity, recorded by an automated locomotor 
activity testing machine, revealed the ability of valdecoxib to 
maintain rearing activity closer to that of control-saline-
treated mice (B) and to their baseline prior to MPTP injec-
tion (A). In agreement with the total spontaneous horizontal 
distance results, vertical activity of valdecoxib-treated mice 
was statistically less impaired. Data are means ± SEM for 
eight to twelve mice per group pre-MPTP treatment and six 
to eight mice per group post-MPTP treatment, and were ana-
lyzed by two-way repeated measures ANOVA with Bonfer-
roni post hoc test, *p < 0.05 and ***p < 0.001 compared to 
the saline+vehicle group; #p < 0.05 and ##p < 0.01 com-
pared to MPTP+vehicle group.
COX-2 deficiency showed a protective effect against motor deficit in MPTP-injected miceFigure 8
COX-2 deficiency showed a protective effect against 
motor deficit in MPTP-injected mice. Animals were 
trained on the rod for two consecutive days before intraperi-
toneal MPTP (4 × 15 mg/kg, 1.5 hr interval) or saline injec-
tion. Mice were assessed for their Rotarod performance on 
day 2 (A), 4 (B) and 6 (C) after MPTP injection. Motor defi-
cit is observed in the MPTP-treated animals, but deficiency in 
COX-2 significantly prevents this impairment. Deficiency in 
COX-2 does not affect baseline motor function in the saline-
injected COX-2 HT and KO mice. Data are means ± SEM for 
six to eight mice per group post-MPTP treatment and ana-
lyzed by two-way repeated measures ANOVA with Bonfer-
roni post hoc test, *p < 0.05 compared to the saline+vehicle 
group and #p < 0.05 compared to MPTP+vehicle group.
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bility of COX-2 and designated the amount of COX-2 in
the WT, HT and KO mice as 1.0, 0.5 and 0.0, respectively.
In Fig. 5C &5D and Fig. 5G &5H, the correlation was ana-
lyzed as in Fig. 5A &5B and Fig. 5E &5F only using the
MPTP-treated samples where COX-2 and microglial acti-
vation is induced by MPTP [1]. From the COX-2 inhibitor
study (Fig. 5C &5D), the number of TH-positive neurons
was strongly positively correlated with the number of
Nissl-stained neurons and the amount of the COX-2
inhibitor administered per day (rs ≈ 1.0 and rs = 8.0,
respectively). There was also a strong negative correlation
with the Mac-1-stained reactive microglia (rs ≈ -0.90, p <
0.05, Spearman correlation statistic, Fig. 5D). It is impor-
tant to note that the Mac-1-stained, reactive microglia
counts, showed a strong negative correlation with the
level of the COX-2 inhibitor (rs ≈ -0.80, p < 0.05, Spear-
man correlation statistic, Fig. 5D). These results imply that
decreased activity of COX-2, due to inhibition by val-
decoxib, strongly correlates with higher survival of
dopaminergic neurons and decreased microglial activa-
tion. Similar results were obtained in the COX-2 defi-
ciency study (Fig. 5G &5H), which showed that the
number of TH-positive neurons strongly positively corre-
lated with the number of Nissl-stained neurons (rs ≈ 0.9)
and strongly negatively correlated with the number of
Mac-1-stained reactive microglia and with the level of
COX-2 (rs ≈ -0.80 and rs ≈ -0.90, respectively, p < 0.05,
Spearman correlation statistic, Fig. 5H). Mac-1-stained
reactive microglia counts strongly positively correlate with
the level of COX-2 (rs ≈ 0.90, p < 0.05, Spearman correla-
tion statistic, Fig. 5H). These results indicate a strong cor-
relation of progressive dopaminergic neurodegeneration
with increased COX-2 and increased microglial activation.
Valdecoxib reduces MPTP-induced locomotor activity 
deficits
To determine the behavioral manifestations of the
observed cellular changes, we assessed spontaneous loco-
motor activity by measuring the total distance traveled
and vertical activity for 30 minutes using an automated
open-field activity apparatus. There were no differences
among the mice before MPTP injection (before day 0, Fig.
6A &7A), and horizontal distance and rearing frequency
were similar among all groups. A sharp reduction in dis-
tance from the first day of the behavioral testing (day -20)
to a lesser but consistent baseline level at later days (from
day -19), indicated a habituation effect (Fig. 6A &7A).
Two weeks (day -14) before MPTP injection, Valdecoxib
treatment was started. To determine the effect of val-
decoxib on pre-MPTP mouse behavior, mice were tested
three times during valdecoxib treatment alone (day -10, -
7 and -3) and showed no differences from non-val-
decoxib-treated groups or their own baselines (the dis-
tance traveled during day -17 to day -15). On day zero,
mice were injected with MPTP or saline. At day 1 post-
MPTP injection (Fig. 6B &7B), a marked reduction in
spontaneous activity was observed (***p < 0.001). How-
ever, the reduction of spontaneous activity was likely due
to systemic MPTP side-effects. Nevertheless, on day 1, the
valdecoxib-treated mice, especially the ones treated with
higher dosages of 30 or 50 mg/kg per day, were able to ini-
tiate spontaneous locomotor activity more than the vehi-
cle-treated mice (##p < 0.01, Fig. 6B). Behavioral
performance was tested on multiple days to ensure the
validity of the results. Our previous studies revealed that
MPTP-treated mice recovered from MPTP-induced
hypoactivity after a few days, and their locomotor activity
fluctuated and then stabilized around two weeks (unpub-
lished observation). At two weeks post-MPTP injection,
30 or 50 mg/kg valdecoxib-treated mice recovered to the
level of saline controls while the MPTP-treated vehicle
group remained hypoactive (***p < 0.001) and had a sta-
tistically lower total ambulating distance and decreased
rearing frequency compared to the valdecoxib-treated
group (##p < 0.01, Fig. 6B and #p < 0.05 and ##p < 0.001,
Fig. 7B, respectively). These behavioral results reflect the
cellular protective effects of the COX-2 inhibitor when
provided in sufficient amounts.
MPTP-induced loss of locomotor coordination is alleviated 
in COX-2-deficient mice
To characterize behavior resulting from underlying bio-
logical changes in the COX-2-deficient mice, we assessed
locomotor coordination and balance in 150-second ses-
sions using an automated Rotarod testing apparatus. All
mice were trained and were able to stay on the rotating
rod at a fixed speed of 16 rpm for 150 seconds. Two days
after MPTP injection (Fig. 8A), the WT mice spent signifi-
cantly less time overall on the rotating rod at various
speeds. This is reflected in a low overall rod performance
(ORP) score (*p < 0.05), which implies a loss of motor
coordination. The COX-2-deficient mice significantly
retain postural balance at several speeds for longer periods
of time than the WT mice (#p < 0.05). For both the MPTP-
treated HT and KO mice, the ORPs appeared to be similar
to the saline controls. After day 4, statistical significance
for the difference in ORP between HT and WT mice was
lost. On day 4 (Fig. 8B) and day 6 (Fig. 8C), the HT mouse
performance was between that of the WT and the KO
mice. The sensitivity of this assay may be suboptimal due
to a ceiling effect from the maximum trial length of 150
seconds, the ability of some coordination-impaired mice
to cling onto the rotating treadmill without falling, and
nonspecific effects of high rotation speeds on both
impaired and control mice. The saline WT mice and the
MPTP KO mice remain relatively stable with respect to
time spent on the rod at the different speeds throughout
the experiment. These behavioral data implicate a benefi-
cial effect of reduced COX-2 levels in COX-2-deficient
mice.
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Discussion
The major finding of this study is that the selective COX-
2 inhibitor valdecoxib or deficiency of COX-2 inhibits
microglial activation and protects the nigrostriatal
dopaminergic system against MPTP-induced neurotoxic-
ity and behavioral deficits. This study was conducted in
attempt to fill in the gap within the literature on the effects
of COX-2 inhibition in protecting SNpc dopaminergic
neurons from MPTP-induced neurotoxicity. We inhibited
COX-2 using both pharmacological and genetic
approaches in aged mice (7–9 months old). The HT mice
were included to determine the effects of heterozygosity
for COX-2 on MPTP-induced cellular toxicity and behav-
ioral impairments. This is because COX-2 is an inducible
enzyme, and MPTP may or may not be able to induce the
same magnitude of COX-2 in WT mice as in heterozygous
mice. We are the first to show a potential link between
COX-2 and microglial activation in COX-2 heterozygous
mice in the demonstration of correlations between the
numbers of TH- and Nissl-stained neurons, Mac-1-stained
microglia, and of all genotypes or the three inhibitor dos-
ages of COX-2. We also show that the behavioral benefits
of COX-2 inhibition and deficiency correlate well with the
observed cellular protection.
Non-biased stereological cell counting indicated that
MPTP-treated mice have severe loss of TH-positive neu-
rons in the SNpc while valdecoxib-treated mice, in a dose-
responsive manner, have reduced MPTP-associated
degeneration of dopaminergic neurons. The concordance
between the reduction of TH expression and neurodegen-
eration was made distinctive by the neuronal loss revealed
by quantification of Nissl-stained neurons from adjacent
sections caudal to the TH-stained sections. Thus, it
appears that selective COX-2 inhibition can attenuate
MPTP-induced dopaminergic neurodegeneration. This
result is supported by other investigators that used slightly
different experimental setups [1,26,27]. To ensure that the
results obtained with the COX-2 inhibitor are specifically
related to COX-2, we conducted an analogous experiment
with COX-2-deficient mice. In concurrence with other
laboratories [1,28], COX-2 deficiency protects TH-posi-
tive neurons in the SNpc from MPTP-induced neurotoxic-
ity. The efficacy of an inhibitor to inhibit COX-2 is likely
to give a result intermediate to that of the COX-2 hetero-
zygous (HT) or knock-out (KO) mice. The TH-stained
neuronal bodies in the SNpc were protected as well as the
striatal TH-stained fibers/terminal, which suggests protec-
tion of the nigrostriatal pathway.
Mounting evidence has demonstrated induction of micro-
glial activation in neurodegenerative diseases [11,16,29],
including PD [9,30] and PD animal models [26,31]. It is
controversial whether such activation of microglia is ben-
eficial or detrimental to neurons. Our research sheds light
on the role of activated microglia in neurodegeneration,
as we observed the neuroprotection afforded by selective
COX-2 inhibition or deficiency of COX-2, which corre-
lated with attenuation of microglial activation. Using
selective COX-2 inhibitors, earlier investigators reported
either no inhibition of activated microglia in the mouse
MPTP-induced PD model [1] or decreased activation of
microglia in the rat 6-hydroxy dopamine-induced PD
model [32]. We show for the first time a direct correlation
between COX-2 and microglia activation in the mouse
MPTP model. Using the optical fractionator method to
estimate total cell number, we found a substantial
decrease in the activation of microglia within the SNpc in
MPTP-treated COX-2 HT mice and an even further reduc-
tion in KO mice relative to the MPTP-treated WT mice.
From these results we speculate that COX-2 may play
some role in suppressing the chronic inflammation and
microglial activation that is observed years after MPTP
exposure [33-35]. This secondary inhibition of microglia
activation will be expected to attenuate the progressive
cell loss induced by the inflammatory response.
Using adjacent SNpc sections to stain and count the
number of TH- and Nissl-stained neurons and Mac-1-
stained activated microglia, we performed a correlation
analysis of TH- and Nissl-stained neurons, COX-2 and
Mac-1-stained activated microglia. With all the data ana-
lyzed or with only the data from the MPTP-treated ani-
mals, we can see that the number of TH-stained neurons
has a high positive correlation with the number of Nissl-
stained neurons. This implies that the lower TH count is
due to degeneration of neurons rather than to reduction
of TH expression. The strong negative correlation of Mac-
1 to TH- or Nissl-stained neurons, with or without data
from the non-MPTP-treated animals, implicates a high
number of activated microglia from an MPTP insult co-
exists with dopaminergic neuronal cell death. From the
valdecoxib study, the number of TH-positive neurons was
strongly correlated with the number of Nissl-stained neu-
rons and the magnitude of COX-2 inhibition, but had a
strong negative correlation with the Mac-1-stained reac-
tive microglia. Thus, inhibition of COX-2 correlates with
reduced degeneration of the dopaminergic neurons. We
demonstrate a clear correlation of COX-2 gene expression
to the number of Mac-1-stained, activated microglia or to
the degeneration of dopaminergic neurons (inferred from
TH and Nissl). The WT, HT and KO animals with full
(1.0), half (0.5) and zero (0.0) availability of COX-2 had
a linear positive relationship with the number of activated
microglia (Mac-1) but had an inverse relationship with
the numbers of TH- and Nissl-stained neurons. In addi-
tion, Mac-1-stained reactive microglia counts strongly
positively correlate with COX-2 levels. These results sug-
gest that inhibition or deficiency of COX-2 correlates well
with the amount of microglial activation and with the
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degeneration of the SNpc dopaminergic neurons that
result from MPTP-induced neurotoxicity.
Animal behavior is a result of underlying cellular physiol-
ogy, and the results observed at the cellular level are aug-
mented by the behavioral analysis. We thoroughly
assessed motor movement using an automated locomotor
activity test and Rotarod apparatus. For the total distance
and vertical activity assessment, mice were able to habitu-
ate to the testing protocol, and the results from the habit-
uation period suggest that mice adjust to the setup very
quickly and that the habituated level of activity is much
lower than the first-time exposure. Once adjusted, the
level of spontaneous horizontal travel and vertical activity
were constant for non-MPTP treated animals throughout
the experiment and for all animals prior to MPTP injec-
tion. Moreover, valdecoxib does not affect the movement
of mice pre-MPTP treatment. Our results differ from those
of other investigators who have only reported behavioral
testing one day post-MPTP injection or earlier [27,36-39].
This is likely because we included behavioral measure-
ments at two weeks when the locomotor activity of each
mouse became stable and was more consistent within
each experimental group. Our present study demonstrates
that MPTP significantly reduces total distance traveled and
vertical activity of the mice, and that valdecoxib decreases
MPTP-induced behavioral impairments.
MPTP-induced loss of locomotor balance and coordina-
tion was measured using the Rotarod test after the mice
were able to habituate to the machine and the procedure.
Pre-training ensured that all the mice could walk on the
rod for at least 150 seconds at 16 rpm. As a result, the per-
formance differences we observed post-MPTP injections
were unlikely due to individual differences in adapting to
a new environment or in strength, but were rather due to
the MPTP-induced loss of locomotor coordination or bal-
ance. Consistent with the protection seen at the cellular
level, the COX-2 HT mouse performance was intermedi-
ate to the WT and KO, although the HT mice behaved gen-
erally closer to the KO than the WT mice. The
heterozygous mice have half the WT level of COX-2 [25],
and this may explain the pharmacological benefits of
reducing COX-2 activity because they exhibit less MPTP-
induced Parkinson's disease-like pathology and symp-
toms as shown in this study. Therefore, it is reasonable to
infer that 50% inhibition of COX-2 activity may be suffi-
cient for a protective benefit in this model.
We hypothesized that COX-2 inhibition or deficiency
mediates effects involved in the neuroprotection of the
SNpc dopaminergic neurons in MPTP-induced mouse
parkinsonism. This means that the differences in neuronal
degeneration or microglial activation are not due to any
effects of COX-2 inhibition on MPTP metabolism or
MPP+ accumulation but are due to inhibition of COX-2
mediated neurotoxicity. This is because it has been shown
that the ratio between the amount of MPTP given and the
amount of MPTP reaching the brain is constant and that
concentrations of 1-methyl-4-phenylpyridinium (MPP+)
in the striatum are similar regardless of age [40], with var-
ious kinds of COX-2 inhibitors used at different doses
[1,27], or in COX-2 KO mice [1].
Based on earlier studies, we assume that microglial activa-
tion occurs before massive death of the dopaminergic
neurons [41]. From our study, activated microglia appear
in COX-2 KO and WT mice injected with saline, which
demonstrates that COX-2 is not required for all microglial
activation. We defined this as basal microglial activation;
however, we did observe a significant reduction in MPTP-
induced microglial activation in the COX-2 KO and inhib-
itor-treated mice relative to the MPTP-treated WT mice.
COX-2 has been proposed to mediate microglial activa-
tion through the generation of reactive oxygen species [9].
Therefore, we speculate that COX-2 inhibition may medi-
ate secondary microglia activation, which perpetuates the
chronic inflammatory response seen in MPTP-induced
PD. Studies from our group and from others have shown
that activated microglia can cause dopaminergic neuronal
death by releasing nitric oxide [10,14,42,43], superoxide
free radicals [44], or proinflammatory cytokines like
tumor necrosis factor-α [45]. Microglia can also induce
neuritic beading [46] or synaptic stripping along dendrites
[47] leading to synaptic disconnection and loss of trophic
support and cell death [32,48]. Thus, activation of micro-
glia may play an important role in secondary injury by
releasing cytokines, reactive oxygen species, and nitric
oxide which is important in the progressive loss of neu-
rons and the perpetuation of the inflammatory response
observed in PD. In microglial culture, COX-2 inhibitors
reduce inducible nitric oxide synthase expression in
lipopolysaccaride-activated microglia [49]; therefore
reducing nitric oxide production, which suggests a posi-
tive modulatory effect of exogenous COX-2 inhibitor on
activated microglial toxic substances release. The
dopaminergic neurons of the SNpc are vulnerable to
inflammation-induced oxidative stress because dopamine
metabolism and autoxidation generate reactive oxygen
species [50]. Consequently, the COX-2-mediated enzy-
matic reaction contributes to dopaminergic neuronal
death by oxidizing dopamine to a reactive dopamine qui-
none [51], by increasing DNA oxidation [7], or through
increased microglial activation leading to chronic inflam-
mation.
To what extent is dopaminergic neuronal death attributa-
ble to microglial activation as opposed to a direct effect of
cyclooxygenase-mediated reactions? Using the activated
microglial inhibitor minocycline, Przedborski's group
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showed that activated microglia contribute to about 20%
of the MPTP-induced TH-positive cell death [52]. The
same group also showed 30–40% neuroprotection by the
COX-2 inhibitor rofecoxib leaving 74–88% neuronal sur-
vival after MPTP injection but failed to show inactivation
of microglia by COX-2 inhibition or deficiency [1]. The
differences between their findings and ours may be due to
different experimental settings, procedures, or technical
variables, such as using different COX-2 inhibitors, pre-
treatment time with the inhibitors, drug/toxin dosages, or
unequal ages of mice. In addition, the previous work
examined microglial activation at early stages following
MPTP administration; thus, it is possible that examina-
tion of pathology at later stages is a better indicator of
microglial activation. Moreover, a direct neurotoxic role
of COX-2 activation cannot explain why COX-2 inhibitors
may be protective or toxic in different PD models or sys-
tems [1,53]. As Wang et al. suggested, the final effect of
inflammation may vary depending on the balance
between neurotrophic and neurotoxic factors released by
activated microglia in different systems or approaches,
and the discrepancy thus may be due rather to an indirect
role of COX-2 in neurotoxicity through regulation of
inflammation [17]. The current result could be because of
differences in the persistence of neuronal abnormalities or
microglial activation.
Our study suggests a temporal and spatial relationship
between microglial activation and neurodegeneration.
Our data is supported by others who also reported this
relationship which is accompanied by COX-2 induction
[1,26,52]. This suggests that COX-2 may mediate micro-
glial activation and play a key role in amplifying the
inflammatory response and other toxic effects, which ulti-
mately exacerbates dopaminergic neuronal loss. From
Teismann et al. and Sugama et al[1,26], we can infer that
COX-2 and activated microglia play an important role in
secondary injury of dopaminergic neurons and in the per-
petuation of inflammatory responses since their levels
became noticeably high a few days after the MPP+ expo-
sure had already induced the primary loss of the
dopaminergic neurons. Damaged neurons can activate
microglia, and as Wu et al. showed, the blockade of micro-
glial activation by minocycline prevents MPTP-induced
neurotoxicity with evidence of reduced microglial-derived
cytotoxic mediators, such as the formation of mature
interleukin-1β, the activation of NADPH-oxidase and
inducible nitric oxide synthase [52]. This suggests that
microglial activation and release of toxic substances
occurs before the secondary or progressive death of the
dopaminergic neurons. Our data as well as those of
Sugama et al. suggest that a prolonged oxidative and
inflammatory environment, which follows the initial
toxic insult, leads to the subsequent loss of neurons that
have been compromised but may have potentially revers-
ible damage [26]. In our MPTP paradigm, about 50% of
the compromised dopaminergic neurons with reversible
damage will die within one to two weeks of the initial
injury. In this study, we believe that valdecoxib treatment
rescues this population of compromised neurons, which
is why we observed the neuroprotective properties
afforded by valdecoxib (Fig. 9). Therefore, inhibition of
COX-2 by valdecoxib or deficiency of COX-2 appears to
be able both directly and indirectly to reduce dopaminer-
gic neurodegeneration and progression to behavioral def-
icits induced by MPTP, possibly through the attenuation
of microglia activation.
We have not repeated those experiments done by previous
groups of investigators, which support our studies. From
the previous works by Teismann et al. and others [1,26],
Schematic flow chart depicting the role of the vicious circle in dop minergic neurotoxic tyFigure 9
Schematic flow chart depicting the role of the vicious 
circle in dopaminergic neurotoxicity. For this study, the 
initial insult MPP+ exerts direct dopaminergic neurodegener-
ation (~30% of the original numbers). Neuronal damage initi-
ates the vicious circle with COX-2 and microglia as the key 
components feeding oxidative and inflammatory damage to 
the neurons, which in turn progresses to the secondary dam-
age/death which is coupled to the release of factors that initi-
ate another cycle of oxidative and inflammatory insults. The 
positive feed back loop may continue until the additional neu-
ronal death (~50% of the remaining of the initial death) com-
bined with the initial loss exceed the amount needed for 
normal motor control (~80% total loss); thus the PD symp-
toms, such as postural instability or hypokinesia, occurs. This 
vicious circle helps explain the chronic and prolong nature of 
PD progression. It is hypothesized that the blockade of 
COX-2 activity by selective COX-2 inhibitors or deficiency 
of COX-2 would attenuate the vicious circle and alleviate 
dopaminergic neurotoxicity by directly reducing COX-2 free 
radical production as well as by indirectly decreasing micro-
glial activation and subsequent microglia-mediated damage.
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we have not overlooked another possible interpretation of
our results: that microglia may become inactive faster
without COX-2. In general, activated immune cells
including microglia become inactive over time through
normal regulatory processes. Indeed, it has been shown
that peak activation of microglia occurs around day 2–3
after MPTP injection, after which microglial activation dis-
sipates [1,26]. Our results show extended activation of
microglia two weeks after MPTP injection although this
degree of activation is less than that seen during the first
few days by other investigators. We also show much lesser
amounts of activated microglia in COX-2-deficient or
COX-2-inhibited mice. We conclude that COX-2 plays a
role in sustaining microglial activation, or that activated
microglia may be excluded persistent activation if COX-2
is lacking. In other words, our results showed that COX-2
inhibition or deficiency may be related to decreased
microglia activation. With time, activation of microglia
declines as COX-2 inhibition helps to reduce the perpetu-
ation of a vicious circle that leads to chronic inflammation
and secondary neurodegeneration.
Conclusion
Our results provide strong support for the hypothesis that
an exacerbated inflammatory process, potentially as a
result of COX-2 mediated microglial activation, is detri-
mental to dopaminergic neurons; and that inhibition of
COX-2 prevents progression of PD-like pathology and
symptoms by breaking a vicious circle of perpetual micro-
glial activation, thus producing the neuroprotective prop-
erties we observe. This is based on the strong correlations
we find between COX-2 levels and microglial activation or
dopaminergic neurodegeneration. We also present an
alternative hypothesis that COX-2 inhibition or deficiency
assists in attenuating microglial activation over time,
which reduces the progression of the inflammatory
response and reduces the perpetuation of the vicious circle
instead of inhibiting microglial activation at the early
stage when initial injury occurs. This alternative hypothe-
sis does not affect our major point: that inhibiting COX-2
reduces the progression of the inflammatory response by
breaking the vicious circle of dopaminergic neuronal cell
death. This study suggests that COX-2 plays an important
role in the secondary activation of microglia, in the pro-
gression of the inflammatory response, and in the pro-
gressive loss of the dopaminergic neurons in MPTP-
induced PD. Therefore, COX-2 may serve as a potential
target for the development of therapeutic strategies to
treat the progressive cell loss observed in PD.
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